![]() |
|
|
Department of Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada H3C 3J7
Received June 2, 2003; accepted November 6, 2003
| Abstract |
|---|
|
|
|---|
-adrenergic agonist that stimulates adenylyl cyclase activity and cAMP levels, inhibited IP3 production by about 35, 30, and 50%, respectively, whereas dideoxyadenosine (DDA), an inhibitor of adenylyl cyclase activity, and oxotremorine stimulated IP3 production by about 90 and 80%, respectively, in these cells, suggesting a functional interaction between these two signaling pathways. Treatment of the cells with antisense oligonucleotide of ANP-C receptor that attenuated ANP-C receptor-mediated inhibition of adenylyl cyclase resulted in a complete attenuation of C-ANP4-23-induced stimulation of IP3 formation, whereas FSK, db cAMP, and ISO-mediated decrease and oxotremorine and endothelin-1 (ET-1)-induced increase in IP3 production was not affected by this treatment. Furthermore, C-ANP4-23-induced increase in IP3 formation was significantly potentiated by DDA and inhibited by FSK and db cAMP, whereas ET-1-induced increase in IP3 production was not affected by FSK. In addition, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H-89), an inhibitor of protein kinase A, completely abolished C-ANP4-23 and not ET-1-induced stimulation of IP3 production. These results indicate that ANP-C receptor activation by C-ANP4-23 and resulting decrease in cAMP levels may be responsible for the activation of phosphatidylinositol (PI) turnover signaling, suggesting a cross-talk between ANP-C receptor-mediated adenylyl cyclase and PLC signaling pathways.
Molecular cloning techniques revealed three subtypes of natriuretic peptide receptor (NPR): NPR-A (Chinkers et al., 1989
; Lowe et al., 1989
), NPR-B (Chang et al., 1989
; Schulz et al., 1989
) and NPR-C (clearance receptor) (Anand-Srivastava et al., 1987
; Fuller et al., 1988
). NPR-A and NPR-B are membrane guanylyl cyclases, whereas NPR-C (or ANP-C receptor) lacks guanylyl cyclase activity. NPR-A catalyzes the production of cGMP in response to ANP and BNP, whereas NPR-B is the target for CNP. The stimulation of cGMP by NPR-A or NPR-B receptor activation has also been reported to inhibit phospholipase C (PLC) signaling (Abdel-Latif, 2001
). On the other hand, ANP-C receptors are coupled to adenylyl cyclase inhibition through inhibitory guanine nucleotide-regulatory protein (Anand-Srivastava et al., 1987
, 1990
).
ANP-C receptors are disulfide-linked homodimers of 64 to 66 kDa that have a single transmembrane domain (Schenk et al., 1985
; Fuller et al., 1988
; Leitman et al., 1988
), an extracellular domain of
440 amino acids, and a short 37-amino acid cytoplasmic domain or tail. We have recently demonstrated that small fragment peptides of the cytoplasmic domain of the ANP-C receptor with complete Gi activator sequence were sufficient to inhibit adenylyl cyclase activity through a pertussis toxin-sensitive Gi protein with the same potency as that of the entire cytoplasmic domain peptide (Anand-Srivastava et al., 1996
; Pagano and Anand-Srivastava, 2001
). In addition, we have also shown that the elimination of the ANP-C receptor by antisense oligonucleotide treatment resulted in the attenuation of C-ANP4-23-induced inhibition of adenylyl cyclase in vascular smooth muscle cells (VSMCs), Leydig tumor cells, and pheochromocytoma cells.
On the other hand, Hirata et al. (1989
) have reported that ANP99-126 and ANP103-123 (atriopeptin) stimulate phosphatidylinositol (PI) turnover in the presence of guanine nucleotides in cultured bovine aortic smooth muscle cell homogenates or particulate fractions. ANP103-123, an atrial peptide analog truncated at the carboxyl terminus that binds selectively to the ANP-C receptor (Leitman and Murad, 1987
), was about 10-fold more potent than ANP99-126 with regard to the formation of inositol phosphates. These results suggested that ANP-C receptors may be coupled to PI turnover signaling through guanine nucleotide-regulatory proteins. Recently, Murthy and Makhlouf (1999
) reported the stimulation of PLC-
activity by C-ANP4-23 and small peptide fragments of cytoplasmic domain of ANP-C receptor in guinea pig tenia coli smooth muscle cells.
Because cAMP and cGMP have been reported to regulate PI turnover (Abdel-Latif, 2001
), it may be possible that the stimulation of PI turnover by atrial natriuretic peptides may be mediated through the inhibition of adenylyl cyclase/cAMP system to which ANP-C receptors are coupled. The present studies were undertaken to investigate this possibility. We have used VSMCs (A10), which have been reported to have both NPR-A/B and ANP-C receptors (Palaparti et al., 2000
). The majority of the receptors in VSMCs are of the ANP-C subtype (Anand-Srivastava and Trachte, 1993
). We have provided the first evidence that the ANP-C receptor-mediated decrease in cAMP levels contributes to the activation of PLC signaling and suggests a cross-talk between ANP-C receptor-mediated adenylyl cyclase and PLC signaling pathways.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture. A10 cell line from embryonic thoracic aorta of rat was obtained from American Type Culture Collection (Manassas, VA). The cells were plated in 7.5-cm2 flasks and incubated at 37°C in a 95% air/5% CO2 humidified atmosphere in Dulbecco's modified Eagle's medium (with glucose, L-glutamine, and sodium bicarbonate) containing antibiotics and 10% heat-activated calf serum. The cells were passaged upon reaching confluence with 0.5% trypsin containing 0.2% EDTA and used between passages 5 and 15.
Antisense and Sense Oligonucleotide Treatment. Antisense treatment of the cells was performed as described previously (Palaparti et al., 2000
). Confluent cell cultures were washed with 5 ml of Dulbecco's modified Eagle's medium containing 10% fetal calf serum and incubated in 2 ml of medium in the absence or presence of 2.5 µM (or as otherwise indicated) antisense or sense oligonucleotide for 48 h at 37°C. After 24-h incubation with antisense or sense oligonucleotide, 5 µCi/ml [myo-2-3H]inositol was added for 24 h. The cells were further treated with C-ANP4-23, FSK, db cAMP, or ISO for 2 h, and the reaction was terminated by adding 0.9 ml of methanol/chloroform/HCl (40:20:1). Cells were then homogenized and the homogenates were used for determination of IP3 levels.
PT Treatment. The confluent VSMCs were incubated for 24 h in a serum-free Dulbecco's modified Eagle's medium with 1 µg/ml PT and 5 µCi/ml [myo-2-3H]inositol. The cells were further treated with ET-1 or C-ANP4-23 for 2 h, and the reaction was terminated by adding 0.9 ml of methanol/chloroform/HCl (40:20:1). Cells were then homogenized and the homogenates were used for determination of IP3 levels.
H-89 (Protein Kinase A Inhibitor) Treatment. The confluent VSMCs were incubated for 24 h in a serum-free Dulbecco's modified Eagle's medium with 5 µCi/ml [myo-2-3H]inositol. The cells were further treated with H-89 (10-5 M) for 30 min and then with C-ANP4-23 for 2 h, and the reaction was terminated by adding 0.9 ml of methanol/chloroform/HCl (40:20:1). Cells were then homogenized and the homogenates were used for determination of IP3 levels.
Determination of IP3 Levels. The confluent VSMCs were incubated for 24 h in a serum-free Dulbecco's modified Eagle's medium with 5 µCi/ml [myo-2-3H]inositol.Cells were washed three times with warm (37°C) Earle's balanced salt solution obtained from Invitrogen (Carlsbad, CA) after removing the cultured medium containing un-incorporated isotope. The cells were further incubated for 30 min in the same buffer containing 20 mM lithium chloride to inhibit the conversion of the inositol phosphates to inositol so that the radiolabeled inositol phosphates could accumulate within the cell (Eid and de Champlain, 1988
; Dean and Beaven, 1989
). Agonists were applied for various periods and the reaction was terminated by adding 0.9 ml of methanol/chloroform/HCl (40:20:1) (Gunther et al., 1982
). The cells were scraped using a rubber policeman and were then homogenized. Chloroform (0.5 ml) and 0.5 ml distilled water were added to the homogenates, and the samples were then centrifuged to separate lipid and aqueous phases. The aqueous phase was transferred to a column containing 0.8 ml of AG1-X8 resin (200-400 mesh, formate form; obtained from Bio-Rad, Hercules, CA) from which inositol phosphates were eluted sequentially with ammonium formate buffers of increasing molarity (Dean and Beaven, 1989
). The radioactivity was measured in a liquid scintillation counter. The lipid phase was counted to measure the phosphatidylinositol pool. The accumulation of inositol phosphate was expressed as the ratio of inositol triphosphate to phosphatidylinositol pool x 103 to correct for the variation in the labeling of the lipid pool.
Statistical Analysis. Data are presented as mean ± S.E.M. Comparison between groups were made using student's t test or analysis of variance where appropriate. The results were considered significantly different at P < 0.05.
| Results |
|---|
|
|
|---|
|
Figure 2A shows the effect of various concentrations of C-ANP4-23 on IP3 production. C-ANP4-23 stimulated IP3 production in a concentration-dependent manner, with an apparent EC50 of about 20 to 30 nM. The maximal stimulation observed was about 70%. The stimulation of IP3 production by C-ANP4-23 (10-7 M) was also time-dependent and peaked at 2 h (Fig. 2B).
|
Effect of db cAMP, FSK, and DDA on IP3 Formation. To investigate the implication of cAMP in PI turnover signaling, we examined the effects of db cAMP and FSK, agents that increase cAMP and DDA, an adenosine analog that inhibits adenylyl cyclase, on IP3 formation. Figure 3 shows that FSK and db cAMP inhibited IP3 formation in A10 SMCs in a concentration-dependent manner. The maximal inhibition of about 35% was observed at 50 µM FSK (Fig. 3A) and 0.1 µM db cAMP (Fig. 3B). In addition, ISO, a
-adrenergic agonist, inhibited IP3 production by about 50% in these cells (Fig. 5). On the other hand, DDA stimulated IP3 production, and maximal stimulation of about 90% was observed at 10 µM DDA (Fig. 3C). These results suggest that cAMP can modulate the production of IP3 in A10 VSMCs; the elevated level of intracellular cAMP inhibits and the reduced level of intracellular cAMP stimulates IP3 formation.
|
|
Effect of ANP-C Receptor Antisense on ANP-C Receptor-Mediated IP3 Production in A10 VSMCs. We have recently shown that ablation of ANP-C receptor by antisense oligodeoxynucleotide treatment of A10 VSMCs resulted in a complete attenuation of ANP-C receptor-mediated inhibition of adenylyl cyclase (Palaparti et al., 2000
). To investigate whether the ablation of ANP-C receptor by antisense treatment also resulted in the attenuation of ANP-C receptor-mediated PI turnover, the effect of sense and antisense treatment on C-ANP4-23-mediated IP3 production was examined in A10 VSMCs. Figure 4 shows that C-ANP-4-23-induced IP3 stimulation was inhibited by antisense treatment. About 65% inhibition was observed when the cells were treated with 1 µM antisense, whereas a complete abolition of C-ANP4-23-stimulated IP3 production was observed at 2.5 µM. However, sense oligomer that has been shown to be ineffective in attenuating ANP-C receptor-mediated inhibition of adenylyl cyclase (Palaparti et al., 2000
) was also unable to attenuate C-ANP4-23-induced stimulation of IP3 production in A10 VSMCs. Furthermore, basal PLC activity was not affected by antisense-oligonucleotide treatment (data not shown).
|
To investigate whether ANP-C receptor antisense also results in the attenuation of other agonist-induced IP3 production, the effect of ANP-C receptor antisense treatment on oxotremorine-, endothelin-, Iso-, FSK- and db cAMP-induced stimulation/inhibition of IP3 formation was examined. The results shown in Fig. 5 indicate that FSK-, db cAMP- and Iso-mediated inhibition or oxotremorine- and ET-induced stimulation of IP3 production was not different in control and antisense-treated cells, whereas C-ANP4-23-mediated stimulation was abolished by antisense oligonucleotide treatment.
Cross-Talk between ANP-C Receptor-Mediated Adenylyl Cyclase and PI Turnover Signaling. To investigate whether ANP-C receptor-mediated decreased cAMP levels contribute to the activation of PI turnover signaling, the effect of cAMP stimulatory and inhibitory agonists on C-ANP4-23-induced stimulation of IP3 production was examined and the results are shown in Fig. 6. db cAMP and FSK inhibited IP3 production significantly (Fig. 6), whereas C-ANP4-23 stimulated IP3 production (Fig. 6). However, when the C-ANP4-23-mediated decrease in cAMP levels was elevated by the addition of db cAMP or FSK, the C-ANP4-23-mediated stimulation of IP3 formation was significantly decreased to control level. For example, C-ANP4-23-mediated IP3 formation that was stimulated by about 75% was almost completely abolished by FSK and db cAMP. However, ET-1-induced increased production of IP3 was not affected by FSK [IP3/phosphatidyl inositol phosphate (%), control, 100%; ET-1, 802.0 ± 15.6; FSK, 60.0 ± 3.0; ET-1 + FSK, 804.0 ± 20]. On the other hand, DDA, which decreased cAMP levels, potentiated the stimulatory effect of C-ANP4-23 on IP3 formation. These results suggest that the ANP-C receptor-mediated decrease in cAMP levels may be responsible for the ANP-C receptor-mediated activation of PI turnover.
|
Effect of Protein Kinase A Inhibitor (H-89) on ANP-C Receptor-Mediated IP3 Production. To further investigate the implication of cAMP/protein kinase A in C-ANP4-23-evoked stimulation of IP3 production, the effect of H-89, a PKA inhibitor, was examined. Figure 7 shows that C-ANP4-23-induced stimulation of IP3 production was completely abolished by pretreatment of the cells with H-89; however, ET-1-induced stimulation of IP3 production was not affected by H-89 treatment.
|
Effect of PT Treatment on ANP-C Receptor-Mediated IP3 Production. ANP-C receptors are coupled to adenylyl cyclase through Gi regulatory protein (Anand-Srivastava et al., 1987
, 1990
). The inactivation of Gi proteins by PT has been reported to uncouple inhibitory hormone receptor from adenylyl cyclase and results in the attenuation of Gi-mediated adenylyl cyclase signaling (Anand-Srivastava et al., 1987
, 1990
). To investigate whether the ANP-C receptor-mediated reduction in cAMP levels is responsible for the C-ANP4-23-induced stimulation of IP3 production, the effect of PT treatment was examined on C-ANP4-23-stimulated IP3 production and the results are shown in Fig. 8. C-ANP4-23-stimulated IP3 production by about 80%, which was completely abolished by PT treatment; however, basal IP3 production was unaffected by PT treatment. On the other hand, increased production of IP3 induced by ET-1 was also not affected by PT treatment.
|
| Discussion |
|---|
|
|
|---|
activity by C-ANP4-23 and small peptide fragments of cytoplasmic domain of ANP-C receptor in guinea pig tenia coli smooth muscle cells. These results suggest that ANP-C receptors may also be coupled to PLC signaling pathway. This notion is further substantiated by our studies showing that ablation of ANP-C receptor by ANP-C receptor antisense attenuates C-ANP4-23-mediated stimulation of PI turnover. The inability of ANP-C receptor antisense oligodeoxynucleotides to block FSK-, db cAMP- and ISO-mediated inhibition or ET-1- and oxotremorine-mediated stimulation of IP3 formation suggests that ANP-C receptor antisense oligonucleotide was specific for ANP-C receptor only and did not affect the other receptor (
-adrenergic, muscarinic, or endothelin) or postreceptor components such as the catalytic subunit of adenylyl cyclase. The ablation of ANP-C receptor by antisense has also been shown to attenuate ANP-C receptor-mediated inhibition of adenylyl cyclase without affecting
-adrenergic receptor-mediated stimulation of adenylyl cyclase and the other components of adenylyl cyclase system (Palaparti et al., 2000
We have also demonstrated a role of cAMP in the modulation of PI turnover signaling in A10 VSMCs in the present studies. FSK (a cAMP-inducing agent), db cAMP, and isoproterenol, inhibited IP3 production, whereas DDA, an inhibitor of adenylyl cyclase and oxotremorine that inhibits adenylyl cyclase through Gi protein, stimulated IP3 formation in A10 VSMCs. Our results are in accordance with other studies showing that cAMP or FSK treatment inhibited basal and
1-adrenergic receptor-induced stimulation of IP3 formation in cultured SMCs from both spontaneously hypertensive and Wistar-Kyoto rats (Wu and de Champlain, 1996
). In addition, a cross-talk between these two signaling pathways, cAMP and PI turnover, has been shown by various studies (Abdel-Latif, 2001
). The activation of cAMP-dependent protein kinase A has been reported to attenuate PLC signaling in a variety of cells (Abdel-Latif, 2001
). G-protein-coupled receptor activation that stimulates adenylyl cyclase and increases intracellular cyclic AMP levels has been shown to decrease IP3 formation (Abdel-Latif, 2001
). In addition, the activation of cGMP-dependent protein kinase by cAMP that results in membrane hyperpolarization has also been reported to inhibit formation of IP3 (Quast, 1993
). However, our studies demonstrate for the first time the interaction between ANP-C receptor-mediated inhibition of adenylyl cyclase activity and increased PI turnover in A10 VSMCs. C-ANP4-23 that inhibited adenylyl cyclase activity and decreased intracellular cAMP levels augmented IP3 formation in A10 VSMCs. However, PT treatment, which inactivates Gi protein and results in the uncoupling of ANP-C receptor from adenylyl cyclase, attenuated ANP-C receptor-mediated stimulation of IP3 production. In addition, protein kinase A inhibitor also attenuated ANP-C receptor-induced augmentation of IP3 production. On the other hand, when the levels of cAMP were increased by FSK (a stimulator of adenylyl cyclase) or by db cAMP, the ANP-C receptor-stimulated IP3 formation was significantly inhibited. On the other hand, FSK was unable to inhibit ET-1-induced increased production of IP3. Furthermore, DDA (an inhibitor of adenylyl cyclase that decreased cAMP levels) potentiated C-ANP4-23-induced increased formation of IP3. These results strongly suggest that ANP-C receptor-mediated inhibition of adenylyl cyclase/cAMP may be responsible for the C-ANP4-23-mediated stimulation of PI turnover; in other words, the stimulation of PI turnover by C-ANP4-23 in A10 VSMCs may be a secondary event mediated through the inhibition of the adenylyl cyclase/cAMP signaling system to which ANP-C receptors are coupled. On the other hand, ET-1-induced increase in production of IP3 was not affected by PT or H-89 treatments, suggesting that ET-1-evoked stimulation of PI turnover is not mediated through Gi protein and protein kinase A activation and may involve Gq protein, a PT-insensitive G protein. Thus, the two peptides stimulate PI turnover by two different mechanisms involving Gi or Gq. This notion was further supported by our results showing an additive effect of the peptides C-ANP4-23 and ET-1 on IP3 production.
In conclusion, we have provided the first evidence to demonstrate that ANP-C receptor activation by C-ANP4-23 inhibits adenylyl cyclase activity and the resulting decreased levels of cAMP contribute to the increased PI turnover in A10 VSMCs (Fig. 9) and suggest a cross-talk between ANP-C receptor-mediated adenylyl cyclase and PI turnover signaling pathways.
|
| Acknowledgements |
|---|
| Footnotes |
|---|
ABBREVIATIONS: ANP, rat natriuretic peptide (28 amino acids); BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide; NPR, natriuretic peptide receptor; C-ANP4-23 [des(Gln18,Ser19,Glu20,Leu21,Gly22)ANP4-23-NH2]; PLC, phospholipase C; VSMC, vascular smooth muscle cell; PI, phosphatidylinositol; FSK, forskolin; DDA, dideoxyadenosine; db, dibutyryl; ET-1, endothelin-1; ISO, isoproterenol; PT, pertussis toxin; H-89, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline; PKA, protein kinase A; IP3, inositol 1,4,5-trisphosphate; SMC, smooth muscle cells.
Address correspondence to: Dr. Madhu B. Anand-Srivastava, Department of Physiology, Faculty of Medicine, University of Montreal, C.P. 6128, succ. Centre-ville, Montreal, Quebec, Canada, H3C 3J7. E-mail: anandsrm{at}physio.umontreal.ca
| References |
|---|
|
|
|---|
Anand-Srivastava MB (1983) Angiotensin II receptors negatively coupled to adenylate cyclase in rat aorta. Biochem Biophys Res Commun 117: 420-428.[CrossRef][Medline]
Anand-Srivastava MB and Cantin M (1986) Atrial natriuretic factor receptors are negatively coupled to adenylate cyclase in cultured atrial and ventricular cardiocytes. Biochem Biophys Res Commun 138: 427-436.[CrossRef][Medline]
Anand-Srivastava MB, Cantin M, and Genest J (1985a) Inhibition of pituitary adenylate cyclase by atrial natriuretic factor. Life Sci 36: 1873-1879.[CrossRef][Medline]
Anand-Srivastava MB, Genest J, and Cantin M (1985b) Inhibitory effect of atrial natriuretic factor on adenylate cyclase activity in adrenal cortical membranes. FEBS Lett 181: 199-202.[CrossRef][Medline]
Anand-Srivastava MB, Sairam MR and Cantin M (1990) Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 265: 8566-8572.
Anand-Srivastava MB, Sehl PD, and Lowe DG (1996) Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem 271: 19324-19329.
Anand-Srivastava MB, Srivastava AK, and Cantin M (1987) Pertussis toxin attenuates atrial natriuretic factor-mediated inhibition of adenylate cyclase. Involvement of inhibitory guanine nucleotide regulatory protein. J Biol Chem 262: 4931-4934.
Anand-Srivastava MB and Trachte GJ (1993) Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 45: 455-497.[Medline]
Anand-Srivastava MB, Vinay P, Genest J, and Cantin M (1986) Effect of atrial natriuretic factor on adenylate cyclase in various nephron segments. Am J Physiol 251: F417-F423.
Berl T, Mansour J, and Teitelbaum I (1991) ANP stimulates phospholipase C in cultured RIMCT cells: roles of protein kinases and G protein. Am J Physiol 260: F590-F595.
Bianchi C, Anand-Srivastava MB, DeLean A, Gutkowska J, Forthomme D, Genest J, and Cantin M (1986) Localization and characterization of specific receptors for atrial natriuretic factor in the ciliary processes of the eye. Curr Eye Res 5: 283-293.[Medline]
Brenner MB, Ballarman BJ, Gunning ME, and Zeidel ML (1990) Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665-699.
Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, and Goeddel DV (1989) Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature (Lond) 341: 68-72.[CrossRef][Medline]
Chinkers M, Garbers DL, Chang M-S, Lowe DG, Chin H, Goeddel DV, and Schulz S (1989) A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (Lond) 338: 78-83.[CrossRef][Medline]
Clavell AL, Stingo AJ, Wei CM, Heulein DM, and Burnett JC (1993) C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 264: R290-R295.
de Bold AJ (1982) Atrial natriuretic factor of the rat heart. Studies on isolation and properties. Proc Soc Exp Biol Med 170: 133-138.[Medline]
de Bold AJ, Borestein HB, Veress AT, and Sonnenberg H (1981) Rapid and potent natriuretic response to intravenous injection of atrial myocardial extractin rats. Life Sci 28: 89-94.[CrossRef][Medline]
Dean NM and Beaven MA (1989) Methods for the analysis of inositol phosphates. Anal Biochem 183: 199-209.[CrossRef][Medline]
Eid H and de Champlain J (1988) Increased inositol monophosphate production in cardiovascular tissues of DOCA-salt hypertensive rats. Hypertension 12: 122-128.
Fuller F, Porter JG, Arfsten AE, Miller J, Schilling JW, Scarborough RM, Lewicki JA, and Schenk DB (1988) Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 263: 9395-9401.
Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA, and Alexander RW (1986) Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 261: 5901-5906.
Gunther S, Alexander RW, Atkinson WJ, and Gimbrone MA Jr (1982) Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol 92: 289-298.
Hamet P, Tremblay J, Pang SC, Garcia R, Thibault G, Gutkowska J, Cantin J, and Genest J (1984) Effect of native and synthetic atrial natriuretic factor on cyclic GMP. Biochem Biophys Res Commun 123: 515-527.[Medline]
Hirata M, Chang CH, and Murad F (1989) Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. Biochim Biophys Acta 1010: 346-351.[Medline]
Leitman DC and Murad F (1987) Atrial natriuretic factor receptor heterogeneity and stimulation of particulate guanylate cyclase and cyclic GMP accumulation. Endocrinol Metab Clin North Am 16: 79-105.[Medline]
Leitman DC, Andersen JW, Catalano RM, Waldman SA, Tuan JJ, and Murad R (1988) Atrial natriuretic peptide binding, cross-linking and stimulation of cyclic GMP accumulation and particulate guanylate cyclase activity in cultured cells. J Biol Chem 263: 3720-3728.
Lowe DG, Chang MS, Hellmis R, Chen E, Singh S, Garbers DL, and Goeddel DV (1989) Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO (Eur Mol Biol Organ) J 8: 1377-1384.[Medline]
Murthy KS and Makhlouf GM (1999) Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem 274: 17587-17592.
Pagano M and Anand-Srivastava MB (2001) Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity. J Biol Chem 276: 22064-22070.
Palaparti A, Li Y, and Anand-Srivastava MB (2000) Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase. Biochem J 346: 313-320.
Quast U (1993) Do the K+ channel openers relax smooth muscle by opening K+ channels? Trends Pharmacol Sci 14: 332-337.[CrossRef][Medline]
Ruskoaho H (1992) Atrial natriuretic peptide: synthesis, release and metabolism. Pharmacol Rev 44: 479-602.[Medline]
Schenk DB, Phelps MN, Porter JG, Scarborough RM, McEnroe GA, and Lewicki JA (1985) Identification of the receptor for atrial natriuretic factor on cultured vascular cells. J Biol Chem 260: 14887-14890.
Schulz S, Singh S, Bellet RA, Singh G, Tubb DJ, Chin H, and Garbers DL (1989) The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell 58: 1155-1162.[CrossRef][Medline]
Stingo AJ, Clavell AL, Aarhus LL, and Burnett JC (1992) Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 262: H308-H312.
Sudoh T, Minamino N, Kangawa K, and Matsuo H (1990) C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168: 863-870.[CrossRef][Medline]
Suga S, Nakao K, Itoh H, Koatsu Y, Ogawa Y, Hama N, and Imura H (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Investig 90: 1145-1149.
Waldman S, Rapport RM, and Murad F (1984) Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334.
Wu L and de Champlain J (1996) Inhibition by cyclic AMP of basal and induced inositol phosphate production in cultured aortic smooth muscle cells from Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens 14: 593-599.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
R. A. Rose and W. R. Giles Natriuretic peptide C receptor signalling in the heart and vasculature J. Physiol., January 15, 2008; 586(2): 353 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hashim, Y. Li, and M. B. Anand-Srivastava Small cytoplasmic domain peptides of natriuretic peptide receptor-C attenuate cell proliferation through Gi{alpha} protein/MAP kinase/PI3-kinase/AKT pathways Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3144 - H3153. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, S. Hashim, and M. B. Anand-Srivastava Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gq{alpha}/MAP kinase signaling pathways Cardiovasc Res, December 1, 2006; 72(3): 464 - 472. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||